<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials
NanoViricides Inc., a clinical stage company specializing in broad-spectrum antivirals, has announced promising results from their recent animal study involving NV-387, a drug candidate aimed at treating Measles. The study utilized humanized mice to simulate Measles infection, as the virus does not naturally infect mice. NV-387 demonstrated a significant increase in survival rates, extending the average lifespan of infected animals from 7.4 days to 17 days, without any observed toxicity. The drug, designed to mimic cellular features essential for viral binding, showed a dose-dependent improvement in survival. These results indicate NV-387's potential as the first drug to effectively treat Measles, as global cases continue to rise.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1050576) on July 21, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。